AstraZeneca faces setback as US FDA extends review period for its breast cancer drug. The decision follows the agency's oncology advisory panel voting against recommending the treatment. This delay represents a significant regulatory hurdle for the pharmaceutical company's oncology pipeline and potential revenue streams.

The FDA's advisory panel typically provides non-binding recommendations but carries substantial influence on final approval decisions. Pharmaceutical stocks often react sharply to regulatory news, especially for cancer treatments where competition remains fierce and market potential reaches billions of dollars annually. Investors will monitor the company's response strategy.

The extended review period increases uncertainty for AstraZeneca's oncology division. The pharmaceutical giant may need to provide additional data or modify its application to address concerns raised during the advisory meeting. This delay could impact the drug's potential market entry timeline and commercial prospects, affecting both patient access and the company's financial performance.